Filing Details
- Accession Number:
- 0001209191-23-024725
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-04-18 19:10:09
- Reporting Period:
- 2023-04-17
- Accepted Time:
- 2023-04-18 19:10:09
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1607678 | Viking Therapeutics Inc. | VKTX | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1606831 | Lawson Macartney | C/O Viking Therapeutics, Inc. 9920 Pacific Heights Blvd, Suite 350 San Diego CA 92121 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, Par Value $0.00001 Per Share | Acquisiton | 2023-04-17 | 20,786 | $8.00 | 68,751 | No | 4 | M | Direct | |
| Common Stock, Par Value $0.00001 Per Share | Disposition | 2023-04-17 | 20,786 | $20.00 | 47,965 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2023-04-17 | 20,786 | $0.00 | 20,786 | $8.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2016-05-26 | 2025-04-28 | No | 4 | M | Direct |
Footnotes
- The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person.
- 100% of the shares subject to the option vested on May 26, 2016, the date of the Issuer's first Annual Meeting of Stockholders following the date of grant.
Billionaire Hedge Funds
